Relief Therapeutics and NeuroX Present Financial Outlook for Merger

Relief Therapeutics Holding SA and NeuroX Group SA have released a joint presentation in anticipation of their upcoming business combination. As the merger is expected to close in mid-December 2025, the companies have outlined a promising financial trajectory.

The merged entity forecasts revenues over CHF 40 million by 2027 and anticipates surpassing CHF 200 million by 2031. Furthermore, the company aims to achieve an EBITDA margin of about 55% by 2028. This projection hinges on the integration and expansion of NeuroX's digital neurotherapeutics offerings.

Details of the financial strategy and strategic vision are available in the presentation on Relief's website. A press conference is scheduled for November 25, 2025, at 3:00 p.m. CET for further discussion.